World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
132
Citations
79053
World Ranking
2286
National Ranking
1293

Overview

Jonathan A. Fletcher is affiliated with Brigham and Women's Hospital in the United States. Their research primarily spans the field of Medicine, with specific focus on Pulmonary and Respiratory Medicine, Oncology, Surgery, Gastroenterology, and Hematology.

Their work covers several topics related to cancer and tumor research, with notable emphasis on sarcoma diagnosis and treatment, gastrointestinal tumor research and treatment, CAR-T cell therapy research, esophageal cancer research and treatment, chronic myeloid leukemia treatments, lymphoma diagnosis and treatment, and soft tissue tumor case studies.

Among their recent publications are:

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor, 2023, Journal of Clinical Oncology
  • Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network, 2020, Annals of Oncology
  • Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST), 2020, Modern Pathology
  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin, 2020, UNC Libraries
  • Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas, 2021, Cancer

The primary venues for Jonathan A. Fletcher's publications include:

  • Journal of Clinical Oncology
  • Diseases of the Esophagus
  • Annals of Oncology
  • Modern Pathology
  • UNC Libraries

Frequent coauthors in their collaborations are:

  • Adrián Mariño-Enríquez
  • Michael C. Heinrich
  • Christopher L. Corless
  • George D. Demetri
  • Heikki Joensuu

Best Publications

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • The landscape of somatic copy-number alteration across human cancers

    Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei

  • PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Anette Duensing;Laura McGreevey

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Biology of gastrointestinal stromal tumors.

    Christopher L. Corless;Jonathan A. Fletcher;Michael C. Heinrich

  • The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

    Jeffrey S. Ross;Jonathan A. Fletcher

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

    Brian P. Rubin;Samuel Singer;Connie Tsao;Anette Duensing

  • High-throughput oncogene mutation profiling in human cancer

    Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler

  • PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma

    Todd G. Kroll;Pasha Sarraf;Lorenza Pecciarini;Chang-Jie Chen

  • Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri

  • Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Robert G. Maki;Christopher L. Corless;Cristina R. Antonescu

  • The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

    Jeffrey S. Ross;Jeffrey S. Ross;Jonathan A. Fletcher;Gerald P. Linette;Gerald P. Linette;James Stec

  • STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

    David A. Tuveson;Nicholas A. Willis;Tyler Jacks;Tyler Jacks;James D. Griffin

  • Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor

    Peter Tontonoz;Samuel Singer;Barry M. Forman;Pasha Sarraf

  • TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

    Brandon Lawrence;Antonio Perez-Atayde;Michele K. Hibbard;Brian P. Rubin

  • KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

    Marcia L. Lux;Brian P. Rubin;Tara L. Biase;Chang Jie Chen

  • Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

    Tanya N. Basu;David H. Gutmann;Jonathan A. Fletcher;Thomas W. Glover

  • Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part Sarcoma: A Distinctive Tumor Entity Previously Included among Renal Cell Carcinomas of Children and Adolescents

    Pedram Argani;Cristina R. Antonescu;Peter B. Illei;Man Yee Lui

  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

    Michael C. Heinrich;Kouros Owzar;Christopher L. Corless;Donna Hollis

Frequent Co-Authors

George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Michael Heinrich
Michael Heinrich Oregon Health & Science University
Christopher D.M. Fletcher
Christopher D.M. Fletcher Brigham and Women's Hospital
Christopher L. Corless
Christopher L. Corless Oregon Health & Science University
Antonio R. Perez-Atayde
Antonio R. Perez-Atayde Boston Children's Hospital
Sheng Xiao
Sheng Xiao Brigham and Women's Hospital
Brian P. Rubin
Brian P. Rubin Cleveland Clinic
Paola Dal Cin
Paola Dal Cin Harvard Medical School
Cynthia C. Morton
Cynthia C. Morton Brigham and Women's Hospital
Samuel Singer
Samuel Singer Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring medical study options beyond the traditional MD, there are many related healthcare degrees and career pathways you can pursue online. These alternatives often allow greater flexibility and faster entry to specialized roles within the healthcare system.

For those interested in pharmacy, a 3 year online pharmd program could be a time-efficient path toward becoming a licensed pharmacist without relocating. Technology-driven fields, such as health records management, are also in high demand; check out an online mhi (Master of Health Informatics) for advanced roles in health information management.

Entry-level, quick-start medical careers are possible too. If you’re curious about coding and insurance processes, you might ask: how much is medical billing and coding school? These programs are short, practical, and can be completed fully online. Aspiring nurse practitioners will be pleased to find flexible and affordable study options with the cheapest np school programs available remotely.

Exploring these online medical and health science degrees can open diverse and rewarding career paths in the growing healthcare sector.

Best Scientists Citing Jonathan A. Fletcher

Trending Scientists